Found: 29
Select item for more details and to access through your institution.
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e1, doi. 10.1016/j.clml.2022.02.001
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 427, doi. 10.1016/j.clml.2022.04.017
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 436, doi. 10.1016/j.clml.2021.12.005
- By:
- Publication type:
- Article
Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 442, doi. 10.1016/j.clml.2022.01.009
- By:
- Publication type:
- Article
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 460, doi. 10.1016/j.clml.2022.01.011
- By:
- Publication type:
- Article
Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 474, doi. 10.1016/j.clml.2021.12.018
- By:
- Publication type:
- Article
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 483, doi. 10.1016/j.clml.2021.12.016
- By:
- Publication type:
- Article
Clinical Characteristics of Posttransplant Lymphoproliferative Disorder After Cord Blood Transplantation Without Antithymocyte Globulin.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 495, doi. 10.1016/j.clml.2021.12.015
- By:
- Publication type:
- Article
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 504, doi. 10.1016/j.clml.2021.12.014
- By:
- Publication type:
- Article
Long-Term Clinical Outcomes and Sequelae of Therapy in Early-Stage Orbital Mucosa-Associated Lymphoid Tissue Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 513, doi. 10.1016/j.clml.2021.12.013
- By:
- Publication type:
- Article
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 523, doi. 10.1016/j.clml.2022.01.012
- By:
- Publication type:
- Article
The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 535, doi. 10.1016/j.clml.2022.01.013
- By:
- Publication type:
- Article
Corrigendum.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 545, doi. 10.1016/j.clml.2022.03.011
- By:
- Publication type:
- Article
Impact of Frailty on Hospital Outcomes Among Patients with Lymphoid Malignancies Receiving Autologous Hematopoietic Stem Cell Transplantation in the United States.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e427, doi. 10.1016/j.clml.2021.12.017
- By:
- Publication type:
- Article
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e435, doi. 10.1016/j.clml.2021.12.012
- By:
- Publication type:
- Article
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e443, doi. 10.1016/j.clml.2021.12.010
- By:
- Publication type:
- Article
Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Granulomatous Myositis as a Manifestation of Chronic Graft-Versus-Host Disease: A Case Series and Review of the Literature.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e459, doi. 10.1016/j.clml.2022.01.004
- By:
- Publication type:
- Article
The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e463, doi. 10.1016/j.clml.2022.01.003
- By:
- Publication type:
- Article
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e467, doi. 10.1016/j.clml.2022.01.002
- By:
- Publication type:
- Article
Impact of Insurance on Overall Survival in Acute Lymphoblastic Leukemia: A SEER Database Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e477, doi. 10.1016/j.clml.2022.01.001
- By:
- Publication type:
- Article
Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e485, doi. 10.1016/j.clml.2022.01.006
- By:
- Publication type:
- Article
Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e495, doi. 10.1016/j.clml.2022.01.010
- By:
- Publication type:
- Article
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e498, doi. 10.1016/j.clml.2022.01.007
- By:
- Publication type:
- Article
Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e507, doi. 10.1016/j.clml.2022.01.016
- By:
- Publication type:
- Article
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e521, doi. 10.1016/j.clml.2022.01.015
- By:
- Publication type:
- Article
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e526, doi. 10.1016/j.clml.2022.01.014
- By:
- Publication type:
- Article
Clinicopathological Factors Associated with the Prognosis and Chronicity of Lymphomatoid Papulosis: A Retrospective Cohort Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e541, doi. 10.1016/j.clml.2022.02.004
- By:
- Publication type:
- Article
Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e549, doi. 10.1016/j.clml.2022.02.003
- By:
- Publication type:
- Article